{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:01:55Z","timestamp":1784757715984,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Positron emission tomography (PET) of the adrenal glands emerged as a non-invasive alternative to adrenal vein sampling (AVS) for treatment selection in primary aldosteronism (PA). The C-X-C-chemokine-receptor type 4 targeting tracer [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PentixaFor showed potential in visualizing aldosterone-producing adenomas. However, standardized diagnostic criteria and experience in European cohorts remain scarce. Here, we report harmonized PET\/CT interpretation criteria, assess their impact on diagnostic agreement, and present a large European tertiary center\u2019s experience with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PentixaFor PET\/CT in PA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between 11\/2023 and 01\/2025, 35 consecutive PA patients underwent [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PentixaFor PET\/CT; 22 also underwent AVS. PET\/CT scans were interpreted in three independent, blinded reads, in which inter-reader agreement was assessed: (i) the routine clinical read by the local team, (ii) an independent review by external molecular imaging experts, (iii) a local re-evaluation using harmonized criteria adapted from experience with [\n                      <jats:sup>11<\/jats:sup>\n                      C]Metomidate PET. Surgical outcomes were analyzed according to Primary Aldosteronism Surgery Outcome (PASO) criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Agreement between local and external readings was 80% (28\/35), increasing to 94% (33\/35) after applying harmonized PET\/CT criteria. Based on local readings, 18\/35 scans (51%) were interpreted as unilateral. In contrast, both the external review and the local team\u2019s re-evaluation classified 11\/35 (31%) as high probability, and 10\/35 (29%) as intermediate probability of unilateral PA. According to local AVS criteria, 10\/14 interpretable AVS indicated unilateral disease, with 8\/10 concordant on PET. Combining successfully and partially cannulated AVS with PET findings, high confidence to diagnose unilateral disease increased to 12\/22 (55%) patients. Twelve patients underwent adrenalectomy with PASO outcomes assessed \u2265 6 months after surgery, identified by AVS, PET or both (n=3, n=8 and n=1, respectively). Complete biochemical remission occurred in 2\/3 operated patients based on AVS, 6\/8 operated patients informed by PET, and 1\/1 guided by both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PentixaFor PET continues to show promise for non-invasive PA subtyping. Harmonized interpretation criteria substantially improved inter-reader agreement. When combined with (partial) AVS, PET increases diagnostic confidence and may expand access to definitive treatment. Further studies are warranted to validate the proposed PET interpretation criteria and better define the subset of patients in whom [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PentixaFor PET\/CT alone might suffice for PA subtyping.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1787233","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:27Z","timestamp":1772515407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world experience with [68Ga]PentixaFor PET\/CT in Primary Aldosteronism using newly developed harmonized diagnostic criteria"],"prefix":"10.3389","volume":"17","author":[{"given":"Linus","family":"Hesse","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]},{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]},{"name":"Pituitary Tumor Center of Excellence at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Herden","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacFarlane","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gillett","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Kienitz","sequence":"additional","affiliation":[{"name":"Endocrinology in Charlottenburg","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Howarth","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreen","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Soll","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Spira","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Butz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina T.","family":"Mogl","sequence":"additional","affiliation":[{"name":"Department of Surgery, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Collettini","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]},{"name":"Pituitary Tumor Center of Excellence at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]},{"name":"Pituitary Tumor Center of Excellence at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]},{"name":"Pituitary Tumor Center of Excellence at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]},{"name":"Department of Human Nutrition, German Institute of Human Nutrition Potsdam-Rehbr\u00fccke","place":["Nuthetal, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Haberbosch","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN)","place":["Berlin, Germany"]},{"name":"Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital","place":["Cambridge, United Kingdom"]},{"name":"Pituitary Tumor Center of Excellence at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism \u2014 a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0254","article-title":"Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism","volume":"156","author":"Liu","year":"2021","journal-title":"JAMA Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00761","article-title":"Molecular imaging versus adrenal vein sampling for the detection of surgically curable primary aldosteronism","volume":"178","author":"Goodchild","year":"2025","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf396","article-title":"Approach to the patient with primary aldosteronism: role of molecular imaging","volume":"110","author":"Teo","year":"2025","journal-title":"J OF Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2255609","DOI":"10.1001\/jamanetworkopen.2022.55609","article-title":"Accuracy of gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism","volume":"6","author":"Hu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07312-0","article-title":"Clinical value of CXCR4-targeted PET-CT in primary aldosteronism: a systematic review and meta-analysis","volume":"52","author":"Tang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"112240","DOI":"10.1016\/j.ejrad.2025.112240","article-title":"Performance of Pentixafor PET\/CT in identifying unilateral primary aldosteronism: A meta-analysis","volume":"190","author":"Gege","year":"2025","journal-title":"Eur J Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"dgz017","DOI":"10.1210\/clinem\/dgz017","article-title":"Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization","volume":"105","author":"Rossitto","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1882-0","article-title":"11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas","volume":"33","author":"Tang","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: A comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","first-page":"P227","article-title":"CXCR4-directed [68Ga]Ga-PentixaFor PET\/CT as a diagnostic modality in subtyping primary aldosteronism","volume-title":"Endocrine Abstracts. European Congress of Endocrinology 2024","author":"Baz","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"dgae747","DOI":"10.1210\/clinem\/dgae747","article-title":"Comparison of different diagnostic criteria of 68Ga-pentixafor PET\/CT for the classification of primary aldosteronism","volume":"110","author":"Zhang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266061","article-title":"Clinical value of 68Ga-pentixafor PET\/CT in subtype diagnosis of primary aldosteronism patients with adrenal micronodules","volume":"65","author":"Ding","year":"2024","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad421","article-title":"The value of targeting CXCR4 with 68Ga-pentixafor PET\/CT for subtyping primary aldosteronism","volume":"109","author":"Zheng","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"109156","DOI":"10.1016\/j.surg.2025.109156","article-title":"Evaluating the value of chemokine receptor type 4\u2013targeted PET imaging in diagnosing primary aldosteronism lateralization: A comparison with adrenal venous sampling","volume":"181","author":"Lu","year":"2025","journal-title":"Surgery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-024-01976-0","article-title":"68Ga-pentixafor PET\/CT is a supplementary method for primary aldosteronism subtyping compared with adrenal vein sampling","volume":"27","author":"Yi","year":"2025","journal-title":"Mol Imaging Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-024-01125-2","article-title":"Clinical value of 68Ga-pentixafor PET\/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study","volume":"14","author":"Zuo","year":"2024","journal-title":"EJNMMI Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01125-2","article-title":"Typing diagnostic value of 68Ga-pentixafor PET\/CT for patients with primary aldosteronism and unilateral nodules","volume":"61","author":"Zuo","year":"2024","journal-title":"Endocrine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1291775","DOI":"10.3389\/fendo.2024.1291775","article-title":"A comparison of the performance of 68Ga-Pentixafor PET\/CT versus adrenal vein sampling for subtype diagnosis in primary aldosteronism","volume":"15","author":"Yin","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00330-022-09058-x","article-title":"Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET\/CT","volume":"33","author":"Gao","year":"2023","journal-title":"Eur Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261964","article-title":"Functional characterization of adrenocortical masses in nononcologic patients using 68Ga-pentixafor","volume":"63","author":"Ding","year":"2022","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.02.012","article-title":"Primary aldosteronism classification with 18-oxocortisol and gallium-68\u2013pentixafor positron emission tomography\/computed tomography","volume":"31","author":"Gao","year":"2025","journal-title":"Endocrine Practice"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04722-0","article-title":"Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism","volume":"47","author":"Ding","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.15204","article-title":"Clinical utility of dual-time 68Ga-pentixafor PET\/CT in diagnosing and subtyping primary aldosteronism","volume":"102","author":"Zuo","year":"2025","journal-title":"Clin Endocrinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13550-025-01309-4","article-title":"Is CXCR4-targeted 68Ga-pentixafor PET\/CT a reliable AVS-free modality for surgical decision-making and prognostic prediction in primary aldosteronism with bilateral adrenal lesions","volume":"15","author":"Shu","year":"2025","journal-title":"EJNMMI Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100384","DOI":"10.1016\/j.jcte.2025.100384","article-title":"68Ga-pentixafor PET\/CT in guiding surgical management of primary aldosteronism","volume":"39","author":"Zheng","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07244-9","article-title":"Total or partial adrenalectomy for aldosterone-producing adenoma: can 68Ga-Pentixafor PET\/CT predict surgical outcomes","volume":"52","author":"Zheng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13550-025-01242-6","article-title":"The prognostic value of CXCR4 PET\/CT imaging in unilateral primary aldosteronism patients after adrenalectomy","volume":"15","author":"Shao","year":"2025","journal-title":"EJNMMI Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-025-00697-w","article-title":"68Ga-pentixafor PET\/CT predict the surgical outcome for the primary aldosteronism","volume":"13","author":"Lin","year":"2025","journal-title":"Clin Transl Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04236-5","article-title":"CXCR4-directed PET with 68Ga-pentixafor versus adrenal vein sampling for the diagnosis of unilateral primary aldosteronism","volume":"89","author":"Tan","year":"2025","journal-title":"Endocrine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3853-7","article-title":"EANM\/EARL FDG-PET\/CT accreditation - summary results from the first 200 accredited imaging systems","volume":"45","author":"Kaalep","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B40","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by conn\u2019s adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02755-7","article-title":"Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial","volume":"405","author":"Argentesi","year":"2025","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography","volume":"76","author":"Sanchez-Crespo","year":"2013","journal-title":"Appl Radiat Isot"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101956","DOI":"10.1016\/j.gendis.2025.101956","article-title":"CXCR4 reduces aldosterone synthesis via regulating CYP11B2 expression","author":"Chen","year":"2025","journal-title":"Genes Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7150\/thno.100848","article-title":"18F]AlF-NOTA-pentixather PET\/CT of CXCR4 in patients with suspected primary hyperaldosteronism","volume":"14","author":"He","year":"2024","journal-title":"Theranostics"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268425","article-title":"A phase I\/IIa clinical trial to evaluate safety and adrenal uptake of para-chloro-2-[18F]Fluoroethyletomidate in healthy volunteers and patients with primary aldosteronism","volume":"66","author":"Gillett","year":"2025","journal-title":"J Nucl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263864","article-title":"Development of fluorinated NP-59: A revival of cholesterol use imaging with PET","volume":"63","author":"Brooks","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1787233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:29Z","timestamp":1772515409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1787233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":47,"alternative-id":["10.3389\/fendo.2026.1787233"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1787233","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1787233"}}